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Abstract 
 
Prevention of mother-to-child transmission of HIV-1 (MTCT) remains a challenge in most 
resource-limited settings, particularly in Africa. Single-dose and short-course antiretroviral 
(ARV) regimens are only partially effective and have failed to achieve wide coverage despite 
their apparent simplicity. More potent ARV combinations are restricted to pregnant women 
who need treatment for themselves but are also infrequently used. Furthermore, postnatal 
transmission via breastfeeding is a serious additional threat. Modifications of infant feeding 
practices aim to reduce breast-milk HIV transmission: replacement feeding is neither 
affordable nor safe for the majority of African women, and early breastfeeding cessation (e.g. 
prior to 6 months of life) requires substantial care and nutritional counselling to be practised 
safely. The recent roll out of ARV treatment has changed the paradigm of prevention of 
MTCT. To date, postnatal ARV interventions that have been evaluated target either maternal 
ARV treatment to selected breastfeeding women, with good efficacy, or single-drug post-
exposure prophylaxis for short periods of time to their neonates, with a partial efficacy and at 
the expense of acquisition of drug-related viral resistance. We hypothesize that a viable 
solution to eliminate paediatric AIDS lies in the universal provision of fully suppressive ARV 
regimens to all HIV-infected women through pregnancy, delivery, and covering the entire 
breastfeeding period. Based on the available evidence, we suggest translating into practice 
the recently available evidence on this matter without any further delay. 
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The purpose of this viewpoint is to review the current challenges in the science of 
prevention of mother-to-child transmission of HIV-1 (MTCT) in breastfeeding populations. 
First, we describe the unmet scientific needs that account for the partial failure of MTCT 
prevention efforts in resource-constrained settings (managerial and operational obstacles to 
successful programme scale-up, while important, are not reviewed here). Second, we argue 
that expanding access to highly active antiretroviral therapy (HAART) therapy presents an 
unprecedented opportunity to radically reduce the burden of paediatric AIDS worldwide, 
through the universal use of antiretroviral (ARV) regimens in pregnant and breastfeeding 
women. 
 
Prevention of MTCT in Africa: Past successes and current programmatic challenges 
 
MTCT can occur in utero, during delivery, or through breastfeeding, and is 
responsible for the majority of paediatric HIV infections. Each day, an estimated 1,600 
children become infected with HIV worldwide, 90% of whom live in sub-Saharan Africa, 
where vertically-acquired HIV disease remains a major contributor to child mortality [1]. 
Scientific successes have been achieved over the past decade to prevent MTCT with the 
development of effective ARV interventions. However, this prevention is to date challenging 
in Africa [2-5]. This relative failure of MTCT prevention at the public health level is mostly 
explained by three reasons [3]: (1) global coverage of HIV testing and counselling remains 
unsatisfactorily low and too few women are offered effective interventions to prevent MTCT; 
(2) the mainstay intervention of single-dose nevirapine (NVP) prophylaxis is moderately 
effective and induces viral drug resistance in HIV-infected mothers and infants; and (3) 
prevention of breastfeeding transmission has remained largely elusive. 
 
The need for effective interventions to prevent HIV transmission through 
breastmilk 
 
As detailed in Table 1, short-course peripartum prophylaxis with one or more ARV 
drugs reduces the MTCT risk around delivery [6], but the subsequent risk of postnatal 
transmission remains high in settings where prolonged breastfeeding is practised [7]. Various 
infant feeding interventions, such as early breastfeeding cessation or replacement feeding 
from birth, can reduce or eliminates, respectively the postnatal transmission risk without 
increasing infant mortality in well-supported research settings [8-10]. However, when 
introduced under routine circumstances, such interventions are often associated with higher 
mortality, morbidity, and stigma, often to the extent that their MTCT prevention benefit is 
completely eliminated [11-13]. As a result, the implementation of these interventions remains 
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largely untenable at a population level and is not recommended as a public health approach 
by the World Health Organization (WHO).  
Maternal HAART with three ARV drugs initiated in pregnancy and continued during 
lactation might represent an alternative intervention that allows safe breastfeeding, especially 
when water availability and uninterrupted supplies of breastmilk substitutes are not assured 
[14]. Indeed, HAART reduces the infectivity of all body secretions and thus lowers HIV 
transmission [15, 16]. The safety and efficacy of this strategy is currently being assessed 
among women in Africa within intervention trials using a variety of ARV regimens. 
Acceptable, efficient, and safe ARV interventions aimed at preventing HIV 
transmission for the majority of women, i.e. with very few restrictions,  are needed in 
resource-limited settings.  
 
The need for alternatives to ARV regimens with a single dose of nevirapine 
 
Short-course peripartum ARV regimens administered to HIV-infected pregnant 
mothers and their infants in resource-constrained settings typically involve intrapartum and 
neonatal single-dose NVP and may be supplemented with antenatal zidovudine (ZDV) and/or 
lamivudine (3TC). These regimens produce MTCT risk reductions ranging from 37 to 77% 
compared to no intervention [17-23]. But one-tenth to two-thirds of women who take a single-
dose of NVP will develop viral resistance to the non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) [24]. This problem can be substantially reduced by combining the use of 
single-dose NVP with short-courses of 3TC (± ZDV) for 7 days after delivery [25, 26]. A 
single intrapartum dose of tenofovir and emtricitabine will also reduce this NNRTI resistance 
by half [27]. None of these approaches fully eliminates the selection of drug-resistant virus. 
The main drawback is that these NNRTI resistance mutations will reduce the effectiveness of 
a subsequent NNRTI-based HAART (the WHO recommended first-line treatment) initiated 
within six months of exposure to single-dose NVP [28, 29]. Previous single dose of 
nevirapine did not compromise the efficacy of subsequent NNRTI-based HAART started 6 
months or more after delivery [28-30]. Anyhow, there is an unmet need for optimal ARV 
regimens aimed at reducing MTCT, while not compromising the therapeutic response to 
HAART in women requiring it later for their own health.  
 
The need for interventions tailored for women presenting at delivery with 
unknown HIV status 
 
HIV testing for pregnant women in antenatal clinics is usually not routinely performed: 
an estimated 18% of pregnant women in sub-Saharan Africa received an HIV test in 2007 
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[31]. In this context, most women present late in pregnancy or even in the labour ward 
unaware of their HIV status. These women may be offered ARV regimens partially effective, 
such as single dose NVP,  and usually no intervention for preventing postnatal transmission 
[32]. Such interventions induce viral resistance to NNRTIs, thus depriving these women of 
attaining the full benefits of ARV therapy once it needs to be initiated. As a result, 
interventions taking into these women and strategies to increase the proportion of pregnant 
women knowing their HIV results [33] are needed to improve the coverage and quality of 
prevention of MTCT in Africa.  
 
The challenge of enhancing the roll-out of MTCT prevention 
 
Global PMTCT service coverage remains unacceptably low in sub-Saharan Africa 
(34%), and is especially poor in western and central Africa (11%) [4, 31]. From a 
programmatic perspective, it is now crucial to speed up the transition from research to wide-
scale practice with innovative, easy to implement interventions that address the overall 
MTCT risk from pregnancy through breastfeeding cessation [3]. All these prevention 
strategies must be ARV-based, safe in pregnancy, labour and lactation, well tolerated, 
durable, and not inducing viral drug resistance. Moreover, the ideal drug combinations would 
also be appropriate in women presenting late for delivery [5, 34]. 
 
The scientific challenges of the prevention of MTCT through breastfeeding 
 
Efficacious PMTCT interventions exist for women eligible for ARV treatment 
 
The risk of HIV transmission through breastfeeding is 3 to 10 times higher among 
women with CD4 count <200 cells/ml than above this threshold [35, 36]. According to WHO 
guidelines, pregnant women with a low CD4 count are eligible for ARV therapy for their own 
health. Once initiated, HAART will rapidly and constantly reduce the maternal viral load in 
plasma and breastmilk, likely reducing the MTCT risk through breastfeeding [37, 38]. 
However, at least two-thirds of HIV-infected pregnant and breastfeeding women are not ill 
enough to require ARV therapy for their own health according to the rather restrictive WHO 
guidelines (CD4 <200 cells/ml, WHO clinical stage IV or CD4 <350 cells/ml and clinical stage 
III) [39]. Thus, in settings where breastfeeding women with low CD4 counts receive HAART, 
while women with higher CD4 counts do not, the majority of postnatal transmission would be 
expected to occur among the healthier women. As shown in Table 2, 80% of the postnatal 
cases of HIV transmission occurred in women with CD4 count >200 cells/ml [35]. In this 
pooled analysis, the breastfeeding duration was 6.4 months in median (inter-quartile range 
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(IQR): 4.4-12.4), which is shorter than durations commonly observed in Africa. Similarly, in 
the ongoing Kesho Bora trial, the 12-month cumulative risk of MTCT was 7.5% (95% CI 2.2-
12.8) among children born to mothers with baseline CD4 count >500 cells/ml who received a 
short-course of ZDV antenatally, a single-dose of intrapartum NVP and no post-partum ARV 
intervention. The median breastfeeding duration was 18 months in this group (IQR: 9-25) [40, 
41]. Thus, the universal use of maternal HAART regimens throughout the entire 
breastfeeding period might represent an attractive solution to the MTCT problem in women 
with moderate to high CD4 counts.  
 
Whether to stop maternal HAART after cessation of breastfeeding 
 
In a context where all HIV-infected pregnant women would be offered HAART, the 
question of whether and when to stop this intervention in women who do not meet WHO 
criteria for treatment is of interest.  
In developed countries, all pregnant women are generally advised to receive a fully 
suppressive HAART regimen until delivery. In such settings, ARV therapy should be initiated 
in adults when the CD4 count reach 350 cells/ml, and international guidelines are currently in 
revision to adjust to this new evidence [42, 43]. In Africa, bacterial infections are among the 
leading causes of early severe morbidity, even among women whose CD4 counts are well 
above 200 cells/ml [44].  
According to the current WHO recommendations, only pregnant and breastfeeding 
women who are eligible for ARV therapy because of their own health should continue 
HAART during the breastfeeding period and beyond in resource-limited settings. Starting 
then stopping HAART for the remaining mothers who do not meet this criteria after delivery 
may be risky.  Studies in non-pregnant adults have suggested that intermittent, CD4-guided 
HAART (i.e. stopping therapy when the CD4 count fell below 350 cells/ml) was associated 
with an increased risk of opportunistic diseases or death [45, 46]. Similarly, a fixed 2-month 
off intermittent therapy lead to a higher proportion of patients with <350 cells/ml [47]. 
We therefore suggest that HAART be initiated for all pregnant and delivering women, 
irrespective of the clinical stage or CD4 count, and continued throughout the breastfeeding 
period. Rules for stopping HAART in the fraction of women who are symptom-free and have 
reached high CD4 counts at the time of breastfeeding cessation (say, 500 cells/ml and 
above) will need to be tailored to the evolving knowledge in this field. We strongly advocate 
for this universal maternal HAART approach that may allow narrowing the gap with the 
rapidly evolving treatment guidelines for adults.  
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Supporting women to make breastfeeding cessation at six months of age 
conceivable, feasible and safe 
 
The provision of maternal HAART to all women, including those who are not eligible 
for treatment, would allow the benefits of breastfeeding in the first months of life whilst 
minimising the HIV transmission risk. This needs to be coupled with breastfeeding cessation 
around six months of age, so that infants are no longer exposed to the MTCT risk beyond 
that age.  
Results from the above-mentioned pooled analysis from Côte d'Ivoire and South 
Africa showed that the overall risk of MTCT was twice as high among children breastfed for 
>6 months than among children breastfed ≤6 months [35]. Breastfeeding beyond six months 
should therefore be avoided when replacement feeding after breastfeeding cessation can be 
safely and sustainably provided, as recommended by WHO [48]. Women need to be 
counselled properly to provide adequate complementary feeding with locally available foods 
to take over breastmilk from six months onwards. Adequate feeding practices around the 
weaning period are indeed crucial for achieving optimal child growth. A study from Côte 
d'Ivoire showed that inadequate complementary feeding at age six months was associated 
with impaired child growth during the following 12 months [49]. In this cohort, the risk of 
stunting was 50% higher in children for whom the dietary diversity was inappropriate in the 
months following the breastfeeding cessation process, than among those adequately fed 
during this crucial period.  
Further research will be required to provide HIV-infected women with innovative 
strategies to reduce the risk of postnatal transmission beyond six months of age while 
ensuring postnatal nutritional support for adequate complementary feeding practices [50]. 
This should be done in addition to, and not as an alternative to, maternal HAART. 
 
The maternal versus infant approach to prevent the postnatal MTCT risk 
 
ARV drugs can be administered to infants as prophylaxis against HIV exposure. In 
Malawi, a very short course of NVP was administered to newborns of HIV-infected women 
presenting late for delivery and who had insufficient time to receive a maternal ARV 
intervention: peripartum MTCT risk was reduced by one third [51].  
More recently, three studies have documented the efficacy of a more extended ARV 
prophylaxis in breastfed infants [52-55] and provide provocative but not entirely satisfactory 
results (Table 3, detailed interpretation of these results in Online Appendix 1).  
Thus, the administration of ARV drugs to breastfed infants is another possible 
strategy to reduce postnatal HIV transmission, especially for children born to women who 
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present late in pregnancy. However, it appears that to be maximally effective this ARV-based 
intervention would need to be maintained throughout the breastfeeding exposure [56] and 
should involve drugs that are not as likely as NVP to select resistant virus and compromise 
the future treatment needs of HIV-infected children. The BAN study, currently underway in 
Malawi, is expected to yield more results on this issue [57]. A new clinical trial (PROMISE-
PEP) is also in preparation in Burkina Faso, Uganda, Zambia and South Africa to evaluate 
infant prophylaxis with lamivudine for a maximum of 38 weeks 
(http://www.clinicaltrials.gov/ct2/show/NCT00640263?term=promise-pep&rank=1). 
 
Universal maternal HAART could largely eliminate the overall MTCT risk 
 
The effect of maternal HAART on HIV load in breastmilk has been reported in  three 
African studies so far. In Mozambique, ARV treatment had been initiated in the third trimester 
of pregnancy and continued for a median duration of three months [37]. In this study, all HIV-
infected women treated with HAART had lower cell-free HIV RNA load in breast milk and 
were less likely to have a detectable breastmilk viral load when compared to untreated 
women. These results are in line with those previously reported in a smaller study conducted 
in Botswana among women with baseline CD4 count <200 cells/ml and treated with HAART 
before and/or after delivery, with breastmilk samples collected three months in median after 
HAART initiation [38]. In this study, HAART had no apparent effect on cell-associated HIV 
DNA load in breastmilk [38]. Similarly, a third study recently conducted in Kenya among 
HAART-treated breastfeeding women showed the suppression of cell-free HIV-1 RNA in 
breastmilk without suppression of HIV-1 DNA in this compartment [58].  
As shown in Table 4, HAART in breastfeeding women results in transmission rates 
generally below 5% in breastfeeding populations (the detailed interpretation of these results 
is provided in Online Appendix 2) [59-65].  
Not negligible in this new perspective is the fact that infants will be exposed to the 
ARV drugs through breastfeeding [38, 66]. These infants’ plasmatic concentrations of the 
transferred drugs vary according to the ARV used. A study in Kenya showed that lamivudine 
and nevirapine, but not zidovudine, were transmitted through breastfeeding to infants in 
biologically significant concentrations when their mothers received these drugs [66]. In 
Mozambique,  detectable concentrations of ARV drugs in breastmilk were found one week 
after delivery in women treated with HAART since 28 weeks of gestational age, despite some 
of them having undetectable plasma levels at the same time [37]. This result suggests a 
possible lag in elimination of ARV drugs in breastmilk. Based on current knowledge, the 
diffusion in breastmilk of Lopinavar/ritonavir and Tenofovir is unknown. Three questions can 
be raised from this growing body of evidence: 1- are these concentrations of ARV drugs safe 
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for infants?; 2- are they effective by themselves against postnatal MTCT?; 3- is there a risk of 
selection of drug-resistant virus in HIV-infected children who will received sub-optimal 
concentrations of ARVs?   
The issue of infant toxicities associated with exposure to maternal HAART is of crucial 
interest. A study in Botswana among breastfed infants born to HAART-treated women 
suggest that hematologic and hepatic toxicities associated with antenatal and postnatal 
exposure to maternal HAART were minimal, with the exception of increased early 
neutropenia that did not persist beyond one month of age [67]. This study also showed that 
excess infant anemia related to either in utero or breastfeeding HAART exposure were not 
detected [67]. Thorne and Newell synthesized recently in an extensive literature review the 
evidence for short to medium-term potential adverse effects and toxicities of exposure to 
antiretroviral drugs in utero and neonatal life (including haematological, mitochondrial, 
teratogenic and carcinogenic effects) [68]. They concluded that "the immense benefits of 
antiretroviral prophylaxis in prevention of mother-to-child transmission far outweigh the 
potential for adverse effects". These adverse effects require further and longer term 
monitoring because they are likely to occur later in childhood [68]. Moreover, the extent and 
effect of infant drug exposure through breastmilk should now be well understood to evaluate 
the benefits and risks of maternal HAART during breastfeeding [66]. 
 
 Conclusions 
 
We suggest the active promotion of the universal maternal HAART approach as a 
way towards elimination of MTCT in resource-limited settings. Such an approach is already 
well established in industrialized countries. We argue that HAART should be made available 
to all HIV-infected pregnant women in resource-limited settings, irrespective of their CD4 
count or clinical stage, and even to those who present late in pregnancy. This universal ARV-
based strategy should be accompanied by proper pharmacovigilance systems. It should 
consider the breastfeeding cessation around six months of age, which implies the need for a 
proper nutritional support. Continuing investigations will compare the safety, acceptability, 
feasibility and efficiency of various maternal HAART regimens for preventing the peripartum 
and postnatal risks of MTCT in order to rank them according to the best risk-benefit balance.  
The gap between the current level of knowledge and the public health implementation 
is still considerable [4, 5]. Expanding the indication of use of potent ARV drug combinations 
to all pregnant, delivering and breastfeeding women aware of their HIV status should be the 
immediate future of MTCT in resource-limited settings. This advanced biomedical approach 
should be closely linked to the development and evaluation of interventions at the community 
level to improve the coverage of HIV testing and counselling among pregnant women, 
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reduce stigma and favour the overall family care approach. Finally, our suggested approach 
is also in line with the recently advocated universal HIV voluntary HIV testing with immediate 
potent ARV treatment [3]. 
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Table 1.  12-24 mother-to-child transmission (MTCT) rates and infant death (95% CI) among 
breastfed children with the provision of peri-partum short-course antiretroviral (ARV) 
regimens to the mother during pregnancy/delivery.  
 
ARV intervention 
Study 
Maternal regimen 
Infant regimen 
Duration 
MTCT risk 
according to baseline 
maternal CD4 count 
 
(95% confidence interval) 
Infant  
infection or death 
(1 – HIV-free survival) 
according to baseline 
maternal CD4 count 
Ditrame & Retro-Ci, 
Côte d'Ivoire 
[69]
 
ZDV 
 
no ARV  
for infants 
from  
36-38 weeks  
of gestation, 
plus 7 days 
post-partum 
 
Among women with  
CD4 <500 cells/mm
3
:  
25.6% at 1.5 Mo (17.9-33.3) 
29.3% at 6 Mo (31.4-37.2) 
38.5% at 12 Mo (29.7-46.3) 
 
Among women with CD4 ≥500 
cells/mm
3
:  
7.7% at 1.5 Mo (3.6-11.8) 
8.8% at 6 Mo (4.5-13.1) 
9.1% at 12 Mo (4.8-13.4) 
Among women with  
CD4 <500 cells/mm
3
:  
28.8% at 1.5 Mo (21.2-36.5) 
32.8% at 6 Mo (24.8-40.6) 
41.0% at 12 Mo (32.0-50.1) 
 
Among women with CD4 
≥500 cells/mm
3
:  
10.2% at 1.5 Mo (5.5-14.8) 
10.8% at 6 Mo (6.0-15.7) 
11.6% at 12 Mo (6.7-16.4 
Ditrame Plus, Côte 
d'Ivoire [70, 71]
 
ZDV+sdNVP 
 
NVP single dose + 
7 days of ZDV for 
infants 
 
ZDV/3TC+sdNVP 
 
NVP single dose + 
7 days of ZDV for 
infants 
 
from 
36 weeks 
of gestation 
 
from 
32 weeks 
of gestation, 
plus 3 days 
post-partum 
 
8.6% at 1.5 Mo (2.9-13.2) 
10.1% at 6 Mo (5.5-14.9) 
15.9% at 18 Mo (9.6-26.5) 
 
 
 
6.2% at 1.5 Mo (3.1-9.9) 
6.8% at 6 Mo (3.6-10.7) 
13.0% at 18 Mo (3.6-10.7) 
 
 
16.8% at 18 Mo (12-24) 
 
 
 
 
 
 
13.6% at 18 Mo (9.6-24.5) 
 
Vertical 
Transmission 
Study, South Africa 
[72] 
 
sdNVP - 21.0% at 18 Mo (19.0-23.1) 24.0% at 18 Mo (22-27) 
 
ZEBS, Zambia 
[73]
 
 
sdNVP - 
Short-term breastfeeding 
21.4% at 24 Mo * 
 
Long-term breastfeeding 
25.8% at 24 Mo * 
Short-term breastfeeding 
32.6% at 24 Mo * 
 
Long-term breastfeeding 
36% at 24 Mo * 
MTCT-Plus,    Côte 
d'Ivoire 
[65]
 
ZDV/3TC+sdNVP 
 
NVP single dose + 
7 days of ZDV for 
infants 
from 
32 weeks 
of gestation, 
plus 3 days 
post-partum 
Among women not eligible  
for ARV therapy: 
3.1% at 1 Mo (0.1-6.7) 
7.5% at 12 Mo (2.8-12.3) 
Among women not eligible 
for ARV therapy:  
12.1% at 12 Mo 
 (6.4–17.9) 
 
* Confidence interval was not available. 3TC: lamivudine; sdNVP: single-dose nevirapine; ZDV: zidovudine. 
 
Median breastfeeding durations were: 
8 months for the Ditrame & Retro-Ci trials; 4 months for the Ditrame Plus study; 6 months for 
the Vertical Transmission Study; 4 and 16 months in the short-term and long-term 
breastfeeding groups of the ZEBS study, respectively; 6 months in the MTCT Plus study.  
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Table 2.  18-month postnatal transmission of HIV among children uninfected at 4 weeks of 
age and according to different thresholds of maternal antenatal CD4 count. 
Pooled analysis of the Vertical Transmission Study (South Africa, 2001-2007) and 
the Ditrame Plus Study (Côte d’Ivoire, 2001-2005). N=1151.  
 
Antenatal maternal 
CD4 count (cells/ml) 
N 
Number of children HIV-
infected through 
breastfeeding 
HIV postnatal 
transmission (%) 
95% 
confidence 
interval 
     
< 200 119 15 15.3 9.5-24.2 
≥ 200 1032 57 6.2 4.9-8.0 
     
< 250 181 20 11.0 5.3-16.2 
≥ 250 970 52 5.4 3.5-6.5 
     
< 350 353 38 12.6 9.3-16.9 
≥ 350 798 34 4.8 3.4-6.6 
     
< 200 119 15 15.3 9.5-24.2 
200-349 234 23 11.3 7.6-16.5 
350-500 320 18 6.3 4.9-9.1 
≥ 500 478 16 3.7 2.3-6.0 
     
 
Adapted from Becquet et al. CROI 2008 [35]
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 Table 3. Mother-to-child transmission (MTCT) rates (95% confidence interval) with the 
provision of antiretroviral post-exposure prophylaxis to the breastfed infant.  
 
Antiretroviral intervention 
Study 
Maternal regimen Infant regimen 
MTCT risk 
 
(95% confidence interval) 
SIMBA, Rwanda [74] 
ZDV+ddI 
 
from 36 weeks of 
gestation to 1 week 
post-partum 
daily NVP or 3TC * 
 
from birth  
up to 6 months 
6.9% at 1 Mo ** 
7.7% at 6 Mo ** 
 
MASHI,  
Botswana [10] 
ZDV+sdNVP 
 
from 36 weeks of 
gestation to 1 week 
post-partum 
daily ZDV 
 
from birth  
up to 6 months 
 
4.6% at 1 Mo ** 
9.0% at 7 Mo ** 
9.5% at 18 Mo ** 
 
MITRA,  
Tanzania [52] 
ZDV+3TC 
 
from 36 weeks of 
gestation to 1 week 
post-partum 
daily 3TC 
 
from birth  
up to 6 months 
3.8% at 1.5 Mo (2.0-5.6) 
4.9% at 6 Mo (2.7-7.1) 
 
PEPI, Malawi [53] 
 
sdNVP 
daily NVP or NVP/ZDV 
 
from birth  
 up to 14 weeks 
Among infants who were HIV-
uninfected at birth  
 
Infant NVP prophylaxis 
5.9% at 9 Mo (3.9-7.0) 
 
Infant NVP/ZDV prophylaxis 
6.4% at 9 Mo (4.9-8.3) 
 
 
SWEN, Ethiopia, 
Uganda, India [55]
 
 
sdNVP 
daily NVP  
 
from birth  
up to 6 weeks 
Among infants who were HIV-
uninfected at birth  
 
2.5% at 1.5 Mo ** 
6.9% at 6 Mo ** 
 
* Similar MTCT rates were observed in both groups.  
** Confidence interval was not available.  
3TC: lamivudine; ddI: didanosine; sdNVP: single-dose nevirapine; ZDV: zidovudine. 
 
Median breastfeeding durations were: 
14 weeks in the SIMBA study; unknown in the MASHI study (mothers instructed to wean at 5 
months); 18 weeks in the MITRA study; unknown in the PEPI study (most infants were 
weaned between 6 and 9 months of age); unknown in the SWEN study (most infants were 
weaned between 14 weeks and 6 months of age). 
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Table 4. 6-12 month mother-to-child transmission (MTCT) rates and infant death (95% 
confidence interval) with the provision of antiretroviral therapy to the mother during 
pregnancy and breastfeeding.  
 
Antiretroviral intervention 
Study 
Maternal regimen 
Infant regimen 
Duration 
MTCT risk 
according to baseline 
maternal CD4 count 
 
(95% confidence 
interval) 
Infant  
infection or death 
(1 – HIV-free survival) 
according to baseline 
maternal CD4 count 
Kisumu, Kenya [64] 
ZDV/3TC+NVP * 
 
NVP single dose 
for infants 
from  
34 weeks  
of gestation 
until 6 Mo 
post-partum 
but continued if 
WHO 
treatment 
criteria were 
met 
Among women with  
CD4 <250 cells/mm
3
:  
4.3% at 1 Mo (1.8-10.0) 
5.2% at 6 Mo (2.4-11.2) 
6.7% at 12 Mo (3.2-13.9) 
Among women with CD4 
≥250 cells/mm
3
: 
3.8% at 1 Mo (2.2-6.3) 
4.9% at 6 Mo (3.1-7.7) 
5.5% at 12 Mo (3.6-8.4) 
not available 
Kesho-Bora,  
Burkina Faso - 
Kenya [40, 41] 
ZDV/3TC+NVP 
 
NVP single dose 
for infants 
from 
18-36 weeks 
of gestation 
Among women with  
CD4 <200 cells/mm
3
:  
6.4% at 12 Mo 
(0.3-12.4) 
Among women with  
CD4 <200: 
10.8% at 12 Mo 
(3.2-18.3) 
MTCT-Plus,    Côte 
d'Ivoire [65] 
ZDV/3TC+NVP 
 
NVP single dose + 
1 week of ZDV for 
infants 
from  
20 weeks  
of gestation 
Among women eligible  
for ARV therapy: 
1.0% at 1 Mo (0.0-3.1) 
3.3% at 12 Mo (0.0-6.9) 
Among women eligible  
for ARV therapy:  
11.2% at 12 Mo 
 (5.0–17.4) 
 
AMATA,  
Rwanda [62] 
 
HAART eligible 
(CD4<350 or stage 
IV): 
D4T+3TC+NVP 
 
Non eligible 
ZDV+3TC+EFZ 
 
NVP single-dose + 
1 week of ZDV for 
infants in both 
strata 
Non eligible: 
from  
28 weeks  
of gestation 
until 7 Mo 
post-partum 
stop 
breastfeeding 
at 6 Mo 
1.3% at 1 Mo (0.4-4.1%)  
1.8% at 1 Mo (0.7-4.8%)  
 
Overall:  
5.0% at 9 Mo 
 (3.0–9.0) 
MITRA-PLUS, 
Tanzania [59] 
ZDV/3TC+NVP 
 
1 week of ZDV-3TC 
for infants 
from  
34 weeks  
of gestation 
until 6 Mo 
postpartum 
continued if 
mother eligible 
for tretament at 
6 Mo 
4.1 % at 1.5 Mo (2.1-6.0) 
5.0% at 6 Mo (3.2-7.0) 
not available 
Dream cohort, 
Mozambique [60, 
61] 
ZDV/3TC+NVP 
 
NVP single dose 
for infants 
from  
15 weeks  
of gestation 
Among women eligible  
for ARV therapy: 
1.2% at 1 Mo **  
2.2% at 6 Mo ** 
2.8% at 12 Mo ** 
not available 
* Half-way through the trial, NVP was replaced by nelfinavir among women with CD4 >250 cells/ml.  
** Confidence interval was not available. 3TC: lamivudine; sdNVP: single-dose nevirapine; ZDV: zidovudine. 
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Online Appendix 1.  
 
The PEPI study, conducted in Malawi, randomised children born to mothers who had 
received single-dose NVP to receive either a neonatal single-dose of NVP and one week of 
ZDV (group 1), or 14 weeks of extended daily infant ARV prophylaxis with NVP (group 2) or 
NVP+ZDV (group 3) [1]. At 9 months of age, the risk of HIV infection was 10.6% in group 1, 
5.2% in group 2 and 6.4% in group 3. However, at 18 months, HIV rates were as high as 
13.9% in group 1, 10.1% in group 2 and 10.2% in group 3. In the SWEN study, conducted as 
parallel randomised trials in Ethiopia, India and Uganda, an extended infant post-exposure 
prophylaxis with daily NVP from birth during six weeks was assessed in breastfed children, 
and compared to single-dose NVP (all mothers had received single-dose NVP) [2]. The 6-
week transmission rate in the extended-NVP arm was 2.5% versus 5.3% in the single-dose 
NVP arm (p=0.009), but the 6-month HIV transmission rate was similar in both study arms: 
8.9% in the extended-NVP arm vs. 6.9% in the single-dose NVP arm (p=0.16). Moreover, 
nearly all (92%) infants who became infected in the extended-NVP arm developed NNRTI 
resistance mutations [3]. In Tanzania, breastfed children received daily 3TC from birth 
through six months of age, while their mothers received daily ZDV+3TC from the third 
trimester of pregnancy until one week post-partum [4]. HIV-transmission rates were 3.8% 
and 4.9% at six weeks and six months of age, respectively. However, the breastfeeding 
duration was considerably shorter than usual African practices (18 weeks in median), and 
only 15% of the children were still breastfed at six months of age. 
 
1. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended Antiretroviral Prophylaxis to Reduce Breast-
Milk HIV-1 Transmission. N Engl J Med 2008;359(2):119-29. 
2. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age 
for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of 
three randomised controlled trials. Lancet 2008 Jul 26;372(9635):300-13. 
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In Kisumu, Kenya, the 12-month transmission rate for children born to mothers with a 
baseline CD4 count >250 cells/ml and receiving ARV therapy from 34 weeks of gestation 
until 6 months post-partum was 5.5% [1]. In this study, the overall transmission attributable to 
breastfeeding was 3.5% at 12 months of age. However maternal HAART was stopped at six 
months of age if WHO treatment criteria were not met, even if children were still being 
breastfed. Thus, among women with baseline CD4 count >250 cells/ml, the postnatal 
transmission risk was 1.7%: 1.1% occurred between months 1 and 6 (i.e. while mothers were 
on ARV treatment), and 0.6% occurred between six and 12 months of age (i.e. after the 
maternal HAART was stopped). Among women with a baseline CD4 count <250 cells/ml, the 
maternal HAART was continued beyond six months of age. The postnatal transmission risk 
in this higher-risk subgroup was 2.4% between months 1 and 12. In Côte d'Ivoire and 
Mozambique, although maternal ARV treatment had been provided to HAART-eligible 
women from the third trimester of pregnancy and throughout the breastfeeding exposure, the 
cumulative postnatal HIV transmission rate (between 1 and 12 months) was 2.3 and 1.6%, 
respectively [2-4]. The postnatal transmission risk between months 1 and 6  was estimated at 
0.8% in Mozambique [3-4], and 0.9% in Tanzania [5]. Finally, the open-label AMATA trial in 
Rwanda yielded the lowest transmission rate ever reported after six months of continuous 
breastfeeding exposure and maternal HAART [6]. More recently, very low transmission rates 
have also been reported at 6 months post-partum in Botswana among women with CD4 
≥200 cells/ml treated with HAART [7], but more detailed data beyond that age are now 
expected. 
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